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Background: Plasmodium vivax merozoite surface protein-1 paralog (PvMSP1P) is a glycosylphosphatidylinositol-
anchored protein expressed on the merozoite surface. This molecule is a target of natural immunity, as high
anti-MSP1P-19 antibody levels were detected during P. vivax infection and the antibody inhibited PvMSP1P-erythrocyte
binding. Recombinant PvMSP1P antigen results in production of a significant Th1 cytokine response in immunized
mice. The present study was performed to characterize natural cellular immunity against PvMSP1P-19 and PvDBP
region II in acute and recovery P. vivax infection.
Methods: Peripheral blood mononuclear cells (PBMCs) from acute and recovery P. vivax infection were obtained for
lymphocyte proliferation assay upon PvMSP1P-19 and PvDBP region II antigen stimulation. The culture supernatant was
examined for the presence of the cytokines IL-2, TNF, IFN-γ and IL-10 by enzyme-linked immunosorbent assay (ELISA).
To determine whether Th1 or Th2 have a memory response against PvMSP1P-19 and PvDBPII protein antigen,
PBMCs from subjects who had recovered from P. vivax infection 8–10 weeks prior to the study were obtained for
lymphocyte proliferation assay. Cytokine-producing cells were analysed by flow cytometry.
Results: IL-2 was detected at high levels in lymphocyte cultures from acutely infected P. vivax patients upon
PvMSP1P-19 stimulation. Analysis of the Th1 or Th2 memory response in PBMC cultures from subjects who
had recovered from P. vivax infection showed significantly elevated levels of PvMSP1P-19 and PvDBPII-specific
IFN-γ-producing cells (P < 0.05). Interestingly, the response of IFN-γ-producing cells in PvMSP1P stimulation
was fourfold greater in recovered subjects than that in acute-infection patients. CD4+ T cells were the major
cell phenotype involved in the response to PvMSP1P-19 and PvDBPII antigen.
Conclusions: PvMSP1P-19 strongly induces a specific cellular immune response for protection against P. vivax
compared with PvDBPII as the antigen induces activation of IFN-γ-producing effector cells following natural
P. vivax exposure. Upon stimulation, PvMSP1P-19 has the potential to activate the recall response of Th1
effector memory cells that play a role in killing the parasite.
Keywords: Plasmodium vivax, PvMSP1P, Cellular immune response, Patients, Infection* Correspondence: pchooton@gmail.com; ethan@kangwon.ac.kr
1Department of Clinical Microbiology and Applied Technology, Faculty of
Medical Technology, Mahidol University, Bangkok, Thailand
3Department of Medical Environmental Biology and Tropical Medicine,
School of Medicine, Kangwon National University, Chuncheon, Gangwon-do
200-701, Republic of Korea
Full list of author information is available at the end of the article
© 2015 Changrob et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Changrob et al. Malaria Journal  (2015) 14:159 Page 2 of 9Background
Plasmodium vivax malaria is the most geographically
widespread Plasmodium species and the second leading
cause of malaria, especially in Southeast Asia and South
America [1]. It persists as an important public health
problem due to the emergence of chloroquine-resistant
P. vivax parasites and the occurrence of severe and fatal
vivax malaria cases [2,3]. An important part of any con-
trol strategy is the implementation of a vaccine capable
of inducing protective immunity against P. vivax.
Two P. vivax vaccine candidates for the exo-erythrocytic
stage, P. vivax circumsporozoite protein (PvCSP) and
P. vivax surface protein 25 (Pvs25), have only entered
clinical trials, whereas others are undergoing preclin-
ical trials. Blood-stage antigens, such as apical mem-
brane protein 1 (AMA-1), merozoite surface protein 1
(MSP-1) and Duffy binding protein (DBP), are abso-
lutely required for vivax invasion of host erythrocytes.
These are responsible for clinical manifestation of vivax
disease and target vaccine candidates [4,5]. A blood-
stage vaccine would be a valuable tool to reduce both
the morbidity and mortality of malaria disease as well
as to decrease parasitemia. Several previous reports
suggested the feasibility of a blood-stage vaccine. First,
immunity against blood-stage antigens can be acquired
as a result of natural exposure to P. vivax infection.
Serological responses to blood-stage antigen and the
inhibitory effect of antibodies against erythrocyte bind-
ing increase with age, suggesting a boosting effect due
to repeated exposure through recurrent infection [6,7].
Second, blood-stage antigen immunisation enhanced
protection against P. vivax infection [5,8]. These data
suggest the immunogenicity of blood-stage antigen.
However, the ability of blood-stage antigen to undergo
rapid mutation presents an important challenge for
vaccine development [9-11]. An effective blood-stage
vaccine must generate both humoral and cellular immune
responses, overcome genetic restriction, and stimulate
memory cells.
Identification of new potential vaccine antigens is
important for the development of a successful novel
blood-stage vaccine. Data regarding humoral and cellular
immune responses against parasite molecules during nat-
ural exposure are required at the epidemiological level [12].
T cells are thought to play a central role in the regulation of
immune responses and the formation of immunological
memory, which can control and eliminate infection. The
identification of T-cell epitopes capable of eliciting an
immune response in individuals of different genetic
backgrounds is necessary for design of a subunit vac-
cine [13,14]. Studies in both mice and humans have
repeatedly shown that proinflammatory cytokines, such
as interleukin-12 (IL-12), gamma interferon (IFN-γ)
and tumour necrosis factor (TNF) are essential mediatorsof protective immunity to erythrocytic-stage malaria para-
sites [15].
With regard to the role of new parasite antigens in the
generation of both humoral and cellular responses, in
this study, cellular immunity against merozoite surface
protein-1 paralog of P. vivax (PvMSP1P) was evaluated
in P. vivax exposed individuals. PvMSP1P is a glycosyl-
phosphatidylinositol (GPI)-anchored blood-stage protein,
but is not closely related to merozoite surface protein-1
(MSP1) (11% identity and 22% similarity) [9,16]. The
molecular mass, number and location of Cys residues on
PvMSP1P are similar to those of PvMSP1, whereas it
shows no hyperpolymorphism in the C-terminal sequence.
PvMSP1P contains double EGF-like domains that play roles
in merozoite invasion. In a previous in vitro study, a cytoad-
herence assay indicated strong binding between pEGFP-
PvMSP1P-transfected COS7 cells and human erythrocytes.
Serological responses to PvMSP1P-19 antigen and the
inhibitory effect of anti-PvMSP1P-19 antibodies were dem-
onstrated in individuals acute P. vivax infection [17]. Sple-
nocytes from mice immunized with PvMSP1P-19 showed
considerate secretion of Th1 cytokines [18]. These data
indicate that PvMSP1P-19 antigen shows high immuno-
genicity in terms of induction of humoral and cellular
immune responses during P. vivax infection. However,
use of PvMSP1P-19 antigen as a novel vaccine candidate
requires an evaluation of the naturally acquired cellular
immune response as well as the memory response of T
cells. This study was performed to evaluate naturally-
acquired cellular immunity against PvMSP1P-19 antigen
in subjects exposed to P. vivax to determine its ability to
stimulate T-cell function and induce a recall response of
memory T cells during P. vivax infection.
Methods
Sample collection
The study was performed in malaria-endemic areas of
southern Thailand where both major species of malaria,
P. vivax and Plasmodium falciparum, are common. Per-
ipheral blood samples were obtained at malaria clinics in
Tha Sae, Chumphon province, which is in the southern
peninsular region of Thailand, from 20 patients with
acute P. vivax infection and 15 convalescing individuals
who had recovered from P. vivax infection about 8–10
weeks prior to the study. The patients were from 18–63
years old. Samples from healthy individuals as controls
were also collected from 20 malaria-naive volunteers
from the Faculty of Medical Technology, Mahidol Univer-
sity, who had no history of exposure to malaria. Venous
blood samples (10 mL) were collected by venipuncture in
heparin tubes for preparation of plasma and peripheral
blood mononuclear cells (PBMCs). Vivax samples were
diagnosed from thick and thin peripheral blood smears
by Giemsa staining. This study was approved by the
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perimentation, Mahidol University, and the Ministry of
Health, Thailand (MUIRB2012/079.2408).Recombinant PvMSP1P-19 protein expression
The gene fragment encoding PvMSP1P-19 was amplified by
PCR from genomic DNA of the P. vivax Sal I strain se-
quence, and cloned into the XhoI and NotI sites of the pEU-
E01-His-TEV-MCS vector (CellFree Sciences, Matsuyama,
Japan). The inserted nucleotide sequence was confirmed
using an ABI PRISM 310 Genetic Analyzer and a BigDye
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA, USA). Highly purified plasmid DNA is re-
quired for in vitro transcription and subsequent translation.
Plasmid DNA was then prepared using a Maxi Plus™ Ultra-
pure plasmid extraction system (Viogene,Taipei, Taiwan) ac-
cording to the manufacturer’s instructions. Purified DNA
was eluted in 0.1× TE buffer (10 mM Tris–HCl, pH 8.0,
1 mM EDTA) and used for recombinant protein expression
by the wheat germ cell-free (WGCF) system (CellFree
Sciences) described previously [19,20]. The recombinant
PvMSP1P-19 protein was purified using a Ni-nitrilotriacetic
acid agarose column (Qiagen, Valencia, CA, USA). Plas-
modium vivax Duffy binding protein (PvDBP) region II,
the expression vector for which was kindly provided by
John H Adams, Department of Global Health, Univer-
sity of South Florida, USA, was expressed as described
previously [21,22].Lymphocyte proliferation assay
Heparinized whole blood was diluted in incomplete
RPMI 1640 medium at a dilution of 1:1. PBMCs were
isolated by overlaying with Ficoll-Hypaque (Stemcell
Technologies, Vancouver, CA, USA) and centrifuged at
2,000 rpm, 20°C for 30 min, and then washed twice with
incomplete RPMI 1640 medium. The PBMCs were then
suspended in complete RPMI 1640 medium containing
10% foetal bovine serum at a density of 3 × 106 cells/mL.
PBMC viability > 90% was required for lymphocyte
proliferation assay (LPA). LPAs were carried out to
evaluate cellular immunity against PvMSP1P-19. Ali-
quots of 2.5 × 105 cells/well of PBMCs were distributed
in triplicate in 96-well flat-bottomed tissue culture plates
(Corning Inc., New York, NY, USA) in a volume of
100 μL. The cells were then stimulated by adding
100-μL of 10-μg/mL purified recombinant antigen
PvMSP1P-19 or PvDBP region II diluted in incomplete
RPMI 1640. The complete RPMI 1640 medium and 2%
v/v of PHA were used as negative and positive controls,
respectively. Cells were cultured for 96 h at 37°C under
5% CO2. After 48 and 96 h, the culture supernatant was
harvested for cytokine detection.Cytokine assay
Cytokine levels in culture supernatant obtained after 48
and 96 h of stimulation with PvMSP1P-19 were mea-
sured using an ELISA Cytokine Kit (BD OptEIA™; BD
Biosciences, San Diego, CA, USA). Briefly, 96-well ELISA
plates were coated with monoclonal antibodies specific to
IL-2, IL-10, IFN-γ and TNF. First, 50 μL of ELISA diluent
were added to each well, and then 100 μL of standard
reagent or culture supernatant were added to duplicate
wells. The plates were shaken for 5 s and incubated for
2 h at room temperature. Streptavidin-horseradish per-
oxidase conjugate mixed with biotinylated anti-human
cytokine antibodies was added, followed by incubation
for 1 h at room temperature. The plates were washed,
followed by addition of 100 μL of chromogenic sub-
strate tetramethybenzidine (TMB) solution to each
well. After incubation for 30 min at room temperature,
the reaction was stopped with 50 μL of stop solution.
The optical density at 450 nm (OD450) was measured
within 30 min after addition of stop reagent. Each ELISA
plate included a human cytokine standard curve, which was
used to calculate cytokine concentrations. All specimens
were analysed in duplicate and the means of the two values
were used in the analyses.
Evaluation of the response of IFN-γ/IL-10 cytokine-
producing cells
To evaluate the response of helper T cells upon PvMSP1P-
19 stimulation, the cell phenotypes were analysed by flow
cytometry (BD FACScanto II; Becton Dickinson, Oxford,
UK). Th1 or Th2 cells were defined by staining with
fluorochrome-conjugated monoclonal antibodies specific to
CD3 (Alexa700), CD4 (PerCP Cy5.5) and CD8 (APC Cy7)
on surface antigen and fluorochrome-conjugated monoclo-
nal antibodies specific to IFN-γ (PE Cy7), IL-2 (APC),
IL-4 (Alexa Fluor488) and IL-10 (PE). Briefly, PBMCs
were plated in 96-well flat-bottomed tissue culture
plates (Corning Inc.) at final concentrations of 5 ×
105 – 1 × 106 cells/well in complete RPMI 1640. Cells
were stimulated by 20 ng/mL PMA plus 1 μg/mL iono-
mycin (Sigma, St. Louis, MO, USA) or 10 μg/mL re-
combinant PvMSP1P-19 antigens. To block cytokine
secretion, 10 μg/mL of Brefeldin A (Sigma) was added
to the culture medium and incubated at 37°C under
5% CO2. After 6 h of stimulation, cells were harvested
into 5-mL polystyrene round-bottomed tubes (Corning
Inc.) in 50 μL of staining buffer (PBS, 1% BSA, 0.1%
NaN3) to determine cytokine production by the acti-
vated T cell population. First, the cell surface was
stained with anti-CD3/CD4/CD8 at 4°C for 15 min and
fixed in 0.5% paraformaldehyde solution at 4°C for
20 min. For intracellular cytokine staining, cells were
permeabilized using the BD Cytofix/Cytoperm buffer
system (BD Biosciences) for 30 min and stained with
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monoclonal antibodies for 20 min in the dark. Finally,
cells were washed and maintained in staining buffer
prior to flow cytometric analysis. Data were analysed
using FlowJo version 7.0 (Tree Star Inc., San Carlos,
CA, USA).Statistical analysis
Data were analysed using the GraphPad Prism software
(San Diego, CA, USA), SigmaPlot (Systat Software, San
Jose, CA, USA) and Microsoft Excel 2007 (Microsoft,
Redmond, WA, USA). One-way ANOVA with Dunnett’s
test was used to evaluate the statistical significance of
differences between the means of each group. In all ana-
lyses, P < 0.05 was deemed to indicate statistical
significance.Figure 1 Cytokine production of PvMSP1P-19-stimulated lymphocyte cultu
PBMCs were re-stimulated with PvMSP1P-19 antigen for 48 h and culture s
48 h of in vitro stimulation. (b) TNF, IFN-γ and IL-10 after 96 h of in vitro stiResults
Lymphocytes from acutely infected P. vivax patients
responding to PvMSP1P-19
To evaluate the immunogenicity of PvMSP1P-19 in in-
duction of PvMSP1P-19-specific T cell function during
P. vivax infection, PBMCs from acutely infected P.
vivax patients were subjected to lymphocyte prolifera-
tion assay. To detect lymphocyte proliferation upon
PvMSP1P-19 stimulation, IL-2 levels in the culture
supernatant were determined by ELISA. The results
showed that PvMSP1P-19 significantly stimulated
IL-2 production, indicating that PvMSP1P-19 induces
lymphocyte proliferation (PvMSP1P-19 = 151.50 ±
132.96 pg/mL, unstimulated = 64.88 ± 44.26 pg/mL,
P < 0.05, Figure 1a). However, the proinflammatory cyto-
kine, TNF, was detected at low levels in cultures of lym
phocytes from acute P. vivax patients (PvMSP1P-19 =res obtained from individuals with acute P. vivax infection (n = 15).
upernatant was removed for cytokine detection. (a) IL-2 detection after
mulation.
Figure 2 The recall of a cellular immune response specific to
PvMSP1P-19 antigen by induction of IFN-γ and IL-10 cytokine responses.
PBMCs from individuals who had recovered from P. vivax infection 8–10
weeks prior to the study were stimulated by PvMSP1P-19 or PvDBPII
antigen with negative (media) and positive controls (PHA) for 96 h. IFN-γ
and IL-10 levels in the culture supernatant were measured by ELISA. Data
show the average cytokine values from P. vivax-recovered subjects
(n = 20). Significance was determined by one-way ANOVA with
Dunnett’s test. The level of significance was set at P < 0.05.
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P > 0.05).
Since cell-mediated immunity was found to be induced
and regulated by cytokines, in this study, the levels of IFN-γ
and IL-10 were measured to identify effector T cell pheno-
type responding to PvMSP1P-19 antigen in acute P. vivax
infection. PvMSP1P-19 stimulation did not induce aTh1 or
Th2 response, as demonstrated by the low levels of IFN-γ
(PvMSP1P-19 = 48.88 ± 73.68 pg/mL, unstimulated =
30.09 ± 30.10 pg/mL, P > 0.05, Figure 1b) and IL-10
(PvMSP1P-19 = 119.17 ± 104.10 pg/mL, unstimulated =
67.32 ± 98.91 pg/mL, P > 0.05, Figure 1b) in PvMSP1P-
19 cultures. The levels of all cytokines produced in
response to PHA were two- to five-fold higher than those
in response to PvMSP1P-19 or PvDBP region II antigen
(Figure 1). Lymphocyte from control subjects not exposed
to malaria showed no significant response of IL-2, TNF,
IFN-γ or IL-10 production upon PvMSP1P-19 stimulation
compared to the medium control. These results suggest
that P. vivax produced PvMSP1P-19-specific effector T
cells in response to natural exposure, and a recall proli-
ferative response of effector cells specific to PvMSP1P-19
occurred after restimulation of these effector cells by
PvMSP1P-19 antigen.
Recall response of IFN-γ and IL-10 cytokines against
PvMSP1P-19 antigen
To evaluate the memory response of lymphocytes on
PvMSP1P-19 stimulation, 15 samples of PBMCs were ob-
tained from P. vivax individuals who had recovered 8–10
weeks prior to the study for lymphocyte proliferation assay.
PvMSP1P-19 significantly stimulated production of IFN-γ
by lymphocytes from recovered subjects compared to
unstimulated controls (PvMSP1P-19 = 176.58 ± 199.05
pg/mL, unstimulated = 38.21 ± 43.09 pg/mL, P < 0.05,
Figure 2). For IL-10, both PvMSP1P-19 and PvDBP region
II antigen strongly induced IL-10 response (PvMSP1P-19 =
113.26 ± 107.90 pg/mL, PvDBPII = 89.59 ± 99.81 pg/
mL, unstimulated = 65.44 ± 80.50 pg/mL, P < 0.05,
Figure 2). The levels of all cytokines produced in response
to PHA were fivefold higher than those in response to
PvMSP1P-19 antigen. Interestingly, upon PvMSP1P-19
stimulation, the IFN-γ levels in lymphocyte cultures from
subjects who had recovered from P. vivax infection,
were increased by four-folds compared to acute P.
vivax patients. Moreover, PvMSP1P-19 induced IFN-γ
production to a level two-folds, that induced by PvDBP
region II (Figure 2). High IFN-γ and IL-10 production
upon PvMSP1P-19 stimulation suggested that individ-
uals recovered from P. vivax in endemic areas are cap-
able of producing memory IFN-γ and IL-10 cells
specific to PvMSP1P-19 antigen. Upon re-exposure to P.
vivax antigen, PvMSP1P-19 antigen showed the ability to
stimulate the memory T-cell response, suggesting thatthese cells are important regulators of the immune re-
sponse to Plasmodium.
CD4+ T cells play a role in the immune response to
PvMSP1P-19 antigen
Many different IFN-γ-producing cell subsets, including
to αβ T cells, γδ T cells and NK cells, have been shown
to be capable of responding to Plasmodium parasites.
Here, the phenotype of cells involved in the IFN-γ and
IL-10 response upon PvMSP1P-19 stimulation was eval-
uated by flow cytometric analysis (Figure 3). Upon
PvMSP1P-19 stimulation, CD4+ T cells were the major
source of IL-2 and IFN-γ production. PvMSP1P-19
stimulation showed significantly higher IL-2 and IFN-γ
levels than the medium control (IL-2, PvMSP1P-19 =
0.070% ± 0.041%, unstimulated = 0.041% ± 0.023%, P <
0.05; IFN-γ, PvMSP1P-19 = 0.112% ± 0.053%, un-
stimulated = 0.037% ± 0.022%, P < 0.05, Figures 4a-b).
The effector CD4+ IFN-γ+ response to PvMSP1P-19
antigen was double that of CD8+ T cells (Figure 4a).
Similarly, PvDBP region II antigen also had a high po-
tential to induce CD4+ IFN+ T cell response (PvDBPII =
0.094% ± 0.046%, unstimulated = 0.037% ± 0.022%,
P < 0.05, Figure 4b). Phenotyping of IL-10-producing
cells upon PvMSP1P-19 stimulation showed that CD4+
and CD8+ T cells were not major sources of IL-10
(CD4+, PvMSP1P-19 = 0.008% ± 0.012%, unstimula-
ted = 0.002% ± 0.002%, CD8+, PvMSP1P-19 = 0.008% ±
0.009%, unstimulated = 0.005% ± 0.007%, P > 0.05,
Figure 5). These data suggest that CD4+ T cells dominate
over CD8+ T cells in the responses against PvMSP1P-19
and PvDBP region II antigens.
Figure 3 T-cell responses to PvMSP1P-19 antigen using multiparameter flow cytometry. Intracellular cytokine assay demonstrating the T-cell
response of P. vivax-recovered subjects to PvMSP1P-19 or PvDBPII with negative (media) and positive controls (PMA/Ionomycin). PBMCs from
individuals who had recovered from P. vivax infection 8–10 weeks prior to the study were removed for lymphocyte proliferation assay and
intracellular cytokine detection by flow cytometric analysis. The data are shown as the average levels of cytokine-producing cells in individual
subjects (n = 6). This shows the gating strategy to identify IL-2/IFN-γ/IL-10-producing cells.
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Here, the immunogenicity of PvMSP1P-19 in terms of
stimulation of cellular immunity was evaluated in sub-
jects exposed to P. vivax both during acute infection and
8–10 weeks following recovery. PvMSP1P-19-specific ef-
fector T cells from acute and recovery P. vivax-exposed
subjects produced IL-2 and IFN-γ after re-stimulation
with PvMSP1P-19 in vitro. CD4+ T cells play a major
role in the immune response against this antigen. The
results of the present study suggest that the immune re-
sponse of PvMSP1P-19-specific T cells is not only readily
induced following P. vivax infection but also persists in
the absence of further exposure.In this study, the ability of PBMCs to produce both pro-
and anti-inflammatory cytokines in response to stimulation
with blood parasite antigen, recombinant PvMSP1P-19
and PvDBP region II antigen was evaluated. PBMCs from
symptomatic P. vivax infection individuals were obtained
in this study as representative of the total malaria-reactive
T-cell pool during P. vivax exposure. Although malaria-
reactive T cells tend to disappear from the peripheral circu-
lation during acute infection, probably migrating to the
spleen and liver, they are released back into the periphery
upon resolution of the infection. Thus, the selection of
peripheral blood as the source of leukocytes has been
validated in many previous studies [23].
Figure 4 T-cell responses to PvMSP1P-19 antigen using multiparameter flow cytometry. (a) Overall PvMSP1P-19-specific IL-2-producing cells.
(b) IFN-γ-producing cells. Significance was determined by one-way ANOVA with Dunnett’s test. The level of significance was set at P < 0.05.
Figure 5 T-cell responses to PvMSP1P-19 antigen using multiparameter
flow cytometry. IL-10-producing cells. Significance was determined by
one-way ANOVA with Dunnett’s test. The level of significance was set
at P < 0.05.
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stimulating the release of cytokines, and this may have
an important function in activating the host’s immune
cells to react to the parasite [24,25]. PBMCs from sub-
jects with acute P. vivax infection produced high levels
of IL-2 but only low levels of IFN-γ and IL-10 were de-
tected in response to PvMSP1P-19 antigen, suggesting
that IFN-γ- and IL-10-producing effector cells specific to
PvMSP1P-19 did not play a major role in killing the para-
site in acute P. vivax infection. A significant IL-2 cytokine
response may assist IL-4/IL-5/IL-13- or IL-17-producing
effector helper cells, as previously shown in studies of cell
expansion in acute malaria [26,27]. Macrophages in acutely
infected PBMC cultures did not produce TNF. Thus,
PvMSP1P-19 protein may not directly induce an inflamma-
tory response, as shown in a previous study in which
malarial pigment and certain glycolipids, such as the
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cytokine TNF [24].
Immune responses to malaria parasites have been shown
to be short-lived following exposure. The response was
based mainly on cellular immunity against individual mal-
aria antigens, and was relatively short-lived, declining within
a few years of exposure [28] or at least being unstable, but
occasionally persisting. However, our understanding of the
memory immune response in malaria remains relatively
poor [29]. The results of the present study demonstrated a
recall response of memory CD4+ T cells in natural P. vivax
exposure. The subsequent cellular immune response in sub-
jects who had recovered from P. vivax infection 8–10 weeks
previously showed significantly elevated IFN-γ responses to
specific PvMSP1P-19 stimulation. CD4+ T cells were the
main source of IFN-γ in response to this antigen. This was
consistent with previous reports that IFN-γ responses are
associated with protection against malaria both among vol-
unteers undergoing experimentally induced infection and
naturally exposed human populations [28,30-33]. Therefore,
elevation of IFN-γ production upon PvMSP1P-19 stimula-
tion could be explained by production of effector Th1 cells
or memory cells specific to PvMSP1P-19 in malaria-
recovered human populations, and that effector cells could
be re-stimulated to produce IFN-γ, indicating a boosting of
cellular immunity in individuals following natural exposure
to the P. vivax parasite. However, further studies are re-
quired to determine the longevity of PvMSP1P-19-specific
Th1 cells and their protective effects against malaria.
Interestingly, this study showed that no evidence of
immediate CD4+ and CD8+ effector cell producing IL-10
upon short-term in vitro PvMSP1P-19 stimulation. IL-10
secretion seemed to occur significant later (accumulating
at 96 h in culture supernatant). Levels of IL-10 cytokine
significantly increased in lymphocyte cultures from sub-
jects who had recovered from P. vivax infection. These
data indicated that regulatory responses by IL-10 produ-
cing cells may reside within the memory population and
that PvMSP1P-19 re-stimulation may be secondary ac-
tivation of Th1 cells. The cellular source of IL-10 in
culture supernatants is not known. There are many
sources of IL-10, being produced mainly by Foxp3+
regulatory T cells [34]. B cells secreting IL-10 in an
antigen specific manner have been described in mice
but the antigen specificity of IL-10-secreting B cells is
poorly documented in humans and they are found at much
lower frequencies than IL-10 producing T cells [35]. Eleva-
tion of IL-10 levels after PvMSP1P-19 stimulation in vitro
supported the sustainability of IL-10-producing effector
cells after parasite clearance, as shown previously [30]. A
balance of pro- and anti-inflammatory cytokines is required
for parasite clearance without inducing excessive host path-
ology. High levels of IFN-γ production consistent with the
IL-10 response upon PvMSP1P-19 stimulation may suggestregulation of the inflammatory response and clearance of
the parasite simultaneously.
A number of blood-stage candidate vaccines have pro-
gressed to clinical trials but none has yet produced good
evidence of protection against clinical malaria. Three of
these vaccine candidates, MSP, AMA1 and DBP, were
designed to induce protective antibodies capable of redu-
cing or blocking parasite growth [36-39]. Here, the re-
sponse of T cells against the merozoite antigen, PvMSP1P-
19, in comparison to PvDBP region II was demonstrated.
PvMSP1P-19 blood-stage antigens stimulated CD4+ T-cell
response, and as a result showed significantly higher IFN-γ
levels in lymphocyte cultures. The activation of CD4+ T
cells specific to PvMSP1P-19 suggests that this antigen can
polarize the Th1 cell response, as shown for MSP1 and
MSP3 antigens [39,40], inducing IFN-γ after re-stimulation
in vitro. The results of the present study support a role for
MSP1P-19 protein in the development of IFN-γ-secreting
T lymphocytes.
Conclusions
PBMCs from subjects who had recovered from P. vivax
infection produced high levels of IFN-γ after PvMSP1P-
19 re-stimulation in vitro. This study suggested that an
immune response consisting of PvMSP1P-19-specific T
cells is induced following infection and had a boosting
effect on cellular immunity in individuals following expos-
ure to the P. vivax parasite. The development of a protect-
ive P. vivax vaccine will require antigen to generate an
effector Th1 cell response as well as the ability to induce
memory cells, such as the specific immune response against
PvMSP1P-19 antigen indicated in this study.
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